NASDAQ:APRE

Aprea Therapeutics Q4 2025 Earnings Results & Report

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 16, 2026. The company reported EPS of -$0.32 versus the -$0.38 consensus estimate, while revenue was $3.34 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Aprea Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
$3.34 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Q4 2025 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.32 per share for Q4 2025, beating the consensus estimate of -$0.38. The report was announced on Monday, March 16, 2026.

Aprea Therapeutics reported revenue of $3.34 thousand for Q4 2025.

Aprea Therapeutics Earnings Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile